Roche Holding AG

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Public

Established: 1896-01-15

Employees: 103.6K

Market Cap: $270.5B

Website: http://www.roche.com

Clinical Trials

Study of Oral RXDX-101 in Adult Patients With Locally Advanced or Metastatic Cancer Targeting NTRK1, NTRK2, NTRK3, ROS1, or ALK Molecular Alterations.

Phase 1

Completed

Conditions: Locally Advanced Solid Tumors
Metastatic Solid Tumors

Interventions: Drug: Entrectinib

First Posted Date: 2014-03-27

Last Posted Date: 2021-06-09

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 84

Registration Number: NCT02097810

Locations: 🇺🇸
Florida Cancer Specialists - Sarasota, Sarasota, Florida, United States
🇺🇸
University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
🇺🇸
Tennessee Oncology, Nashville, Tennessee, United States

and more 7 locations

A Study Examining Maintenance Bevacizumab (Avastin®) Monotherapy in Participants With Advanced Lung Adenocarcinoma

Completed

Conditions: Lung Adenocarcinoma

Interventions: Drug: Bevacizumab

First Posted Date: 2014-03-20

Last Posted Date: 2018-02-23

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 201

Registration Number: NCT02093000

Locations: 🇭🇺
Veszprem Megyei Onkormanyzat Tudogyogyintezet, Farkasgyepu, Hungary
🇭🇺
University of Pecs; 1St Department of Medicine, Pecs, Hungary
🇭🇺
Matrai Gyogyintezet, Matrahaza, Hungary

and more 13 locations

Extension Study to Assess the Efficacy and Safety of Repeat Treatment With Rituximab (MabThera) in Participants With Active Rheumatoid Arthritis (RA)

Phase 2

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Rituximab
Drug: Methotrexate
Drug: Methylprednisolone
Drug: Folic Acid

First Posted Date: 2014-03-20

Last Posted Date: 2017-03-13

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 465

Registration Number: NCT02093026

A Study of CellCept (Mycophenolate Mofetil) in Combination Therapy in Heart Transplant Patients.

Phase 3

Completed

Conditions: Heart Transplantation

Interventions: Drug: mycophenolate mofetil (MMF)
Drug: cyclosporine A (CsA)
Drug: corticosteroids

First Posted Date: 2014-03-19

Last Posted Date: 2014-10-29

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 36

Registration Number: NCT02091414

A Study to Evaluate Efficacy of CellCept (Mycophenolate Mofetil) in Patients With Lupus Nephritis

Phase 3

Terminated

Conditions: Lupus Nephritis

Interventions: Drug: Mycophenolate mofetil (MMF)
Drug: Cyclophosphamide, Maintenance Phase
Drug: Cyclophosphamide, Induction Phase
Drug: Prednisone

First Posted Date: 2014-03-07

Last Posted Date: 2014-07-17

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 16

Registration Number: NCT02081183

An Observational Study Examining the Effect of Added MabThera Therapy in Patients With Untreated Chronic Lymphocytic Leukemia

Completed

Conditions: Chronic Lymphocytic Leukemia

First Posted Date: 2014-03-06

Last Posted Date: 2017-05-31

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 150

Registration Number: NCT02080884

Locations: 🇭🇺
Semmelweis Egyetem Aok; Iii.Sz. Belgyogyaszati Klinika, Budapest, Hungary
🇭🇺
Semmelweis University, First Dept of Medicine, Budapest, Hungary
🇭🇺
National Institute of Oncology, A Dept of Internal Medicine, Budapest, Hungary

and more 12 locations

A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a Single Anti-TNF Inhibitor

Phase 3

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: rituximab [MabThera]

First Posted Date: 2014-03-05

Last Posted Date: 2016-07-29

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 302

Registration Number: NCT02079532

A Study of Avastin (Bevacizumab) in Patients With Multiple Myeloma

Phase 2

Terminated

Conditions: Multiple Myeloma

Interventions: Drug: Bevacizumab

First Posted Date: 2014-03-05

Last Posted Date: 2014-07-08

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 10

Registration Number: NCT02079519

A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants

Phase 3

Active, not recruiting

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Alectinib
Drug: Crizotinib

First Posted Date: 2014-03-03

Last Posted Date: 2024-11-07

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 303

Registration Number: NCT02075840

Locations: 🇺🇸
University of Illinois at Chicago, Chicago, Illinois, United States
🇨🇦
Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada
🇺🇸
Beth Israel Deaconess Med Ctr; Hem/Onc, Boston, Massachusetts, United States

and more 122 locations

A Cross-over Study Examining the Bioequivalence of 3 Test Formulations to a Reference Formulation of Alectinib (RO5424802) in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: Ro542-4802/F03 (Reference)
Drug: Ro542-4802/F07 (Test)
Drug: Ro542-4802/F08 (Test)
Drug: Ro542-4802/F14 (Test)

First Posted Date: 2014-02-28

Last Posted Date: 2023-12-11

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 97

Registration Number: NCT02074553

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy